Publicaciones (155) Publicaciones de José Federico Díaz González

filter_list

2025

  1. Bibliometric analysis of the scientific production of rheumatology departments in Spain during the 2013-2022 period

    Reumatologia Clinica, Vol. 21, Núm. 1

  2. Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

    Health Policy, Vol. 156

  3. Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV-154 in Adults With Glucocorticoid-Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial

    Arthritis and Rheumatology

  4. Study of the impact of the inclusion of global pain and functional capacity assessment in the definition of remission and its maintenance for rheumatoid arthritis. Aims and methodology

    Reumatologia Clinica, Vol. 21, Núm. 5

  5. Tocilizumab modulates the activity of the classical and alternative complement pathways in rheumatoid arthritis patients

    Frontiers in Immunology, Vol. 16

2024

  1. Early identification of golimumab-treated patients with higher likelihood of long-term retention

    Frontiers in Immunology, Vol. 15

  2. Management, development and methodology of the Clinical Practice Guidelines and Recommendations of the Spanish Society of Rheumatology

    Reumatologia Clinica, Vol. 20, Núm. 7, pp. 392-397

  3. Modulation of the K/BxN arthritis mouse model and the effector functions of human fibroblast-like synoviocytes by liver X receptors

    European Journal of Immunology, Vol. 54, Núm. 11

  4. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis

    European Journal of Clinical Investigation, Vol. 54, Núm. 2

  5. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching

    Rheumatology (United Kingdom), Vol. 63, Núm. 7, pp. 1882-1892

  6. Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network

    Arthritis and Rheumatology, Vol. 76, Núm. 4, pp. 587-598

  7. The complement system is linked to insulin resistance in patients with systemic lupus erythematosus

    Clinical and experimental rheumatology, Vol. 42, Núm. 1, pp. 115-121

2023

  1. Development of a web tool to calculate the cumulative dose of glucocorticoids

    Reumatologia Clinica, Vol. 19, Núm. 1, pp. 1-5

  2. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

    The Lancet Regional Health - Europe, Vol. 33

  3. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  4. Expert recommendations for the use of apremilast in psoriatic arthritis

    Reumatologia Clinica, Vol. 19, Núm. 1, pp. 34-44

  5. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

    Advances in Rheumatology, Vol. 63, Núm. 1

  6. Full characterization of the three pathways of the complement system in patients with systemic lupus erythematosus

    Frontiers in Immunology, Vol. 14

  7. HDL Cholesterol Efflux and the Complement System Are Linked in Systemic Lupus Erythematosus

    Journal of Clinical Medicine, Vol. 12, Núm. 16

  8. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

    Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197